Bristol Myers says it needs another year to hit target for new drugs
Drugmaker Bristol Myers Squibb on Thursday pushed back by a year the time frame for its current new-product portfolio to hit $10 billion in sales as the ramp-up of new drugs including anemia treatm...
What's in Store for Bristol-Myers (BMY) in Q3 Earnings?
Investors are likely to focus on Opdivo's demand along with an incremental contribution from newer drugs when Bristol-Myers (BMY) reports Q3 results.
Bristol-Myers Squibb Acquisition Of Mirati Makes Sense
Bristol Myers Squibb is a large pharmaceutical company with a strong dividend yield and impressive assets. The company's recent acquisition of Mirati Therapeutics, including its oncology drug Kraza...
Top Wall Street analysts favor these five dividend stocks during tumultuous times
TipRanks' analyst ranking service pinpoints Wall Street's best-performing stocks, including Cisco and Chesapeake Energy.
Bristol-Myers Squibb: Time To Get Greedy
Buying Bristol-Myers now could be a practical application of Buffett's advice to be greedy when others are fearful. As it stands right now, the pharmaceutical giant is highly concentrated on just t...
Bristol Myers' (BMY) Opdivo SC Meets Kidney Cancer Study Goals
Bristol Myers' (BMY) subcutaneous formulation of Opdivo, developed using Halozyme's Enhanze technology, meets noninferiority goals in a late-stage kidney cancer study compared with intravenous Opdivo.
7 Healthcare Stocks That Can Cure a Lackluster Portfolio
This hasn't been a great year for healthcare stocks. The Dow Jones U.S. Health Care Index is down 4% on the year compared to a 14% gain in the S&P 500 index.
3 Things About Bristol Myers Squibb That Smart Investors Know
Bristol Myers Squibb is looking at its second consecutive year of declining revenue. It is building a pipeline to stem that decline, resulting from patent expirations.
Bristol Myers's injectable kindey cancer drug found non-inferior to IV form
Bristol Myers Squibb said on Thursday its injectable form of blockbuster cancer drug Opdivo was found to be non-inferior to the approved intravenous form in a late-stage trial for treatment of a ty...
2 Biotech Stocks That Could Make You Richer
Bristol Myers is turning to acquisitions and its pipeline to offset a major patent cliff. Novartis just completed a spinoff that should lead to stronger overall growth.
Cancer Biotechs Pique Buyout Interest: Recent Deals in Focus
The M&A trend of 2023 shows that there is an increasing interest in biotech companies making innovative cancer treatments.
Bristol Myers Squibb (BMY) Stock Declines While Market Improves: Some Information for Investors
In the most recent trading session, Bristol Myers Squibb (BMY) closed at $56.61, indicating a -0.09% shift from the previous trading day.
Bristol-Myers Squibb to acquire Mirati in up to $5.8 billion deal
CNBC's Angelica Peebles joins 'Closing Bell: Overtime' to discuss Bristol-Myers Squibb on Sunday said it will acquire cancer drugmaker Mirati Therapeutics for up to $5.8 billion
Pharma Stock Nears 2-Year Low on Multi-Billion Dollar Deal
Shares of major pharmaceutical name Bristol-Meyers Squibb Co (NYSE:BMY) are 0.2% lower at $56.54 at last glance, and touched a nearly two-year low of $55.70, after the company agreed to acquire Mir...
Bristol-Myers is spending $5.8 billion to buy Mirati Therapeutics
Bristol-Myers Squibb Co (NYSE: BMY) has decided to spend up to $5.8 billion to acquire Mirati Therapeutics Inc (NASDAQ: MRTX). Shares of both companies are in the red at writing.
Related Companies